2,4-Oxazolidinedione,3,5,5-trimethyl- cas no:127-48-0

Name2,4-Oxazolidinedione,3,5,5-trimethyl-
CAS127-48-0
Synonyms3,3,5-Trimethyl-2,4-diketooxazolidine;3,5,5-Trimethyl-2,4-oxazolidinedione; Absentol; Edion; Epidione; Epixal;Minoaleviatin; NSC 15799; NSC 169503; Petidion; Petidon; Petilep; Pitmal;Ptimal; Tridion; Tridione; Tridone; Trimedal; Trimetadione; Trimethadion;Trimethadione; Trimethin; Trimetin; Trioxanona; Troxidone
EINECS(EC#)204-845-8
Molecular FormulaC6H9 N O3
Molecular Weight143.14

refractive index1.457

Hazard May have adverse side effects; toxic in overdose.
Risk R61
Safety

The Hazard Codes of Trimethadione (CAS NO.127-48-0):T
Risk Statements: R61:May cause harm to the unborn child. R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: S53:Avoid exposure - obtain special instructions before use. S22:Do not breathe dust. S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
WGK Germany: 3
RTECS: RQ2100000
Human poison by unspecified routes. Moderately toxic experimentally by ingestion, subcutaneous, intraperitoneal, and intravenous routes. An experimental teratogen. Human reproductive effects by ingestion: effects on newborn, including physical and other postnatal measures or effects. Human teratogenic effects by ingestion: developmental abnormalities of the craniofacial, musculoskeletal, cardiovascular, and urogenital systems. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NO_x. See also KETONES.

The toxicity of Trimethadione (CAS NO.127-48-0):

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LDLo	intraperitoneal	2gm/kg (2000mg/kg)	BEHAVIORAL: SLEEP	Journal of Laboratory and Clinical Medicine. Vol. 31, Pg. 1330, 1946.
man	LDLo	unreported	88mg/kg (88mg/kg)		"Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
mouse	LD50	intraperitoneal	2gm/kg (2000mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 134, Pg. 60, 1961.
mouse	LD50	intravenous	2gm/kg (2000mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 31, Pg. 1330, 1946.
mouse	LD50	oral	2100mg/kg (2100mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 377, 1973.
mouse	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		British Journal of Pharmacology and Chemotherapy. Vol. 11, Pg. 141, 1956.
mouse	LD50	unreported	2170mg/kg (2170mg/kg)		United States Patent Document. Vol. #4056540,
rabbit	LD50	intraperitoneal	1500mg/kg (1500mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 31, Pg. 1330, 1946.
rabbit	LD50	intravenous	1500mg/kg (1500mg/kg)		Journal of Laboratory and Clinical Medicine. Vol. 31, Pg. 1330, 1946.
rat	LD50	intraperitoneal	280mg/kg (280mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
rat	LD50	intravenous	160mg/kg (160mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
rat	LD50	oral	2140mg/kg (2140mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 138, Pg. 224, 1962.
rat	LD50	subcutaneous	2gm/kg (2000mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 312, 1972.